Spotlight On... Ill-fated Contrave trial piles more hurt on Orexigen; Lilly drug rep's killer sentenced to life in prison; Carter's pro-Keytruda announcement got social media talking; and more...

Last March, Orexigen ($OREX) landed in hot water with researchers, the FDA and marketing partner Takeda when it blabbed some early trial results that falsely suggested its obesity med could improve cardiovascular outcomes for patients. Just over a year later, it's still facing the consequences. Former FDA deputy commissioner Joshua Sharfstein is calling for U.S. regulators to propose restrictions on the drug, Contrave, to counter the "misleading information" from the California company, Forbes reports. And the FDA has some tools to do that, he noted, including a Risk Evaluation and Mitigation Strategy. More from FiercePharma

> Convicted killer Reginald Potts, Jr., was sentenced to life in prison for murdering his ex-girlfriend, Nailah Franklin, who had been an Eli Lilly ($LLY) sales rep. Report

> AstraZeneca's ($AZN) eye drug candidate MEDI-551 won the FDA's orphan drug designation, which brings additional market exclusivity with it. Report

> Keytruda patient Jimmy Carter's announcement last week that he is cancer-free sent social media abuzz about the Merck & Co. ($MRK) treatment. Report

> Drug-price cuts in China are taking a toll on Big Pharma's sales there, with the pharma market shrinking by 1% from October to November last year. Report

And Finally... How do biotech entrepreneurs choose the names for their startup companies? Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.